Kineta (KANT) Form 3 PROTEOSTASIS THERAPEUTICS / Sheila Wilson ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Wilson Sheila

(Last) (First) (Middle)

C/O PROTEOSTASIS THERAPEUTICS, INC.

80 GUEST STREET, SUITE 500

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/05/2019

3. Issuer Name and Ticker or Trading Symbol
PROTEOSTASIS THERAPEUTICS, INC. [ PTI ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Operating Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	18,586	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	11/01/2026	Common Stock	60,000	6.98	D
Employee Stock Option (Right to Buy)	(2)	03/01/2027	Common Stock	15,000	14.72	D
Employee Stock Option (Right to Buy)	(3)	03/01/2028	Common Stock	24,000	3.11	D

Explanation of Responses:

1. These securities shall vest and become exercisable in a series of installments, with the first installment becoming exercisable for 25% of the underlying common stock on November 1, 2017, and thereafter vesting and becoming exercisable in quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on November 1, 2026, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.

2. These securities shall vest and become exercisable in a series of installments, with the first installment becoming exercisable for 25% of the underlying common stock on March 1, 2018, and thereafter vesting and becoming exercisable in quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on March 1, 2027, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.

3. These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on March 1, 2019, and thereafter vesting and becoming exercisable in quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on March 1, 2028, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.

Remarks:

Exhibit List - Exhibit 24.1 - Limited Power of Attorney

	/s/ Janet L. Smart, Attorney-in-Fact	02/14/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.